Among the six coronavirus vaccine candidates that have entered human trials, two belong to publicly listed U.S. companies: Moderna Inc and Inovio Pharmaceuticals Inc Both stocks have rallied in reaction to updates on R&D and funding.
Moderna is up about 143% year-to-date and Inovio is higher by 265%.
Moderna, Inovio’s Vaccine Candidates
Both Moderna and Inovio use a modern approach as opposed to conventional vaccines that employ a weakened form of the pathogen, a killed pathogen or specific pieces of pathogen such as its protein, sugar or capsid.
Moderna is developing mRNA-1273, an mRNA vaccine, against the new coronavirus in collaboration with the Vaccine Research Center at the NIH’s National Institute of Allergy and Infectious Diseases. It is a vaccine against SARS-CoV-2 encoding for the spike, or S, protein….CLICK for complete article